Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies

Main Article Content

Kim Papp
Jacek C. Szepietowski
Leon Kircik
Darryl Toth
Michael E. Kuligowski
May E. Venturanza
Kang Sun
Eric L. Simpson

Keywords

Atopic Dermatits, Janus Kinase Inhibitor, Topical, Roxulitinib

Abstract

Abstract not available.

References

1. Wei W, et al. J Dermatol. 2018;45(2):150-157.

2. Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018;121(3):340-347.

3. Bao L, et al. JAKSTAT. 2013;2(3):e24137.

4. Oetjen LK, et al. Cell. 2017; 171(1):217-228.

5. Quintas-Cardama A, et al. Blood. 2010;115(15):3109-3117.

6. Kim BS, et al. J Allergy Clin Immunol. 2020;145(2):572-582.